The GI-MAP™ (GI-Microbial Assay Plus) test is the first comprehensive stool analysis to use DNA-based quantitative PCR (qPCR) technology to evaluate GI pathogens, parasites, dysbiotic bacteria, fungi, and more, making it an essential tool for practitioners looking for underlying causes of patient symptoms. And, unlike many other microbiome assays, we have fully validated each target organism on the GI-MAP so that you can have confidence in the results.
The GI-MAP's qPCR technology is a critical tool for integrative and functional medicine practitioners. It provides truly quantitative results that allow you to accurately determine the clinical significance of pathogenic organisms and dysbiosis patterns. Considering these benefits, why would you still rely on culture and microscopy for stool analysis and assessment of the gastrointestinal (GI) environment?
GI-MAP™ tests for GI pathogens, opportunistic organisms, normal flora, and markers of GI health, including:
GI-MAP also assesses H. pylori antibiotic resistance genes, as well as the virulence factors associated with the pathogenicity of H. pylori. Information related to antibiotic resistance and virulence factors can help guide personalized, effective treatment protocols.
Other available stool tests may appear to be DNA-based. But they are, in fact, only using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) to identify stool microbes. Their methodology relies on cultures from stool, which is far less reliable than results provided using qPCR technology. Culture-based tests cannot measure strict anaerobes, and they don't deliver true quantitation of reported organisms.
Reproducibility is of crucial importance to the practitioners and patients that rely on the efficacy of the GI-MAP. To achieve it, we perform rigorous quality control, and have validated all molecular target quantification assays.
The GI-MAP is the most accurate, comprehensive DNA stool analysis available. It provides consistently accurate, actionable results that help practitioners identify and treat root causes of conditions, including, but not limited to:
GI-MAP™ was developed by Diagnostic Solutions Laboratory (DSL). DSL was founded to bridge the gap between healthcare providers and the clinical laboratory. Their commitment is to serve the clinical needs of the health care provider with cutting-edge laboratory medicine by utilizing proven methodologies that are accurate and reliable. By working with experienced clinicians and opinion leaders throughout multiple medical disciplines, they are able to build assays that are clinically relevant and provide actionable results.
The highly experienced scientists at DSL have developed over 500 assays in their careers. They are empowered to validate every analyte and use the best methodology available to be sure the results you receive are accurate and precise. Their production team adheres to the strictest standards with an emphasis on quality and a realization that every sample belongs to a patient. Customer service and technical support teams are dedicated to helping patients, clinicians and their staff understand our testing and the process of working with Diagnostic Solutions Laboratory in a seamless manner.